Clinical and Immunological Considerations of Monoclonal Antibody Therapy in COVID-19
A Review
DOI:
https://doi.org/10.48112/acmr.v4i1.47Keywords:
monoclonal antibodies, interleukin-6, Covid-19Abstract
Abstract Views: 51Currently, effective methods for the prevention and treatment of coronavirus infections have not been developed. This could be attributed to the unique pathogenesis of the coronavirus infection and the rapid global spread of the pandemic, which have posed challenges to ongoing research efforts. Similar to other viral infections, coronavirus infection leads to the development and dissemination of the inflammatory process, resulting in viremia or the systemic spread of the infection. This uncontrolled inflammatory response is characterized by elevated levels of cytokines such as IFNy, IL-1, IL-6, and IL-12 in the bloodstream, transitioning the initial inflammatory reaction into a phase known as the cytokine storm. The cytokine storm is marked by severe clinical and laboratory manifestations. Consequently, it is crucial to implement appropriate therapies that target the uncontrolled inflammation induced by the virus rather than viremia itself. Hence, the aim of our study was to investigate the impact of monoclonal antibodies, specifically the medication "Kazirivimab + Imdevimab," which is a combination of recombinant monoclonal antibodies targeting the S-protein, on the clinical progression and laboratory parameters in patients with COVID-19.
References
Hosseini A, Hashemi V, Shomali N, Asghari F, Gharibi T, Akbari M, Gholizadeh S, Jafari A. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother. 2020;132:110859. doi: 10.1016/j.biopha.2020.110859.
Matucci A, Maggi E, Vultaggio A. Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects. Front Immunol. 2015;5:690. doi: 10.3389/fimmu.2014.00690.
Aguiar JA, Tremblay BJ, Mansfield MJ, Woody O, Lobb B, Banerjee A, et al. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur Respir J. 2020;56(3):2001123. doi: 10.1183/13993003.01123-2020.
Anastassopoulou C, Russo L, Tsakris A, Siettos C. Data-based analysis, modelling and forecasting of the COVID-19 outbreak. PLoS One. 2020;15(3):e0230405. doi: 10.1371/journal.pone.0230405.
Fairman KA. COVID-19 Infection Fatality Rates. Health Aff (Millwood). 2020;39(8):1462. doi: 10.1377/hlthaff.2020.00949.
Morabito CJ, Gangadharan B. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19. Clin Transl Sci. 2020;13(5):835-837. doi: 10.1111/cts.12816.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9.
Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20(25):7-13. doi: 10.2807/1560-7917.es2015.20.25.21163.
Guo C, Li B, Ma H, Wang X, Cai P, Yu Q, et al. Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. bioRxiv, 2020:029769. doi: 10.1101/2020.04.08.029769
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11. doi: 10.1186/s40779-020-00240-0.
Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268–271. doi: 10.34172/aim.2020.09.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001.
Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi: 10.1183/13993003.00607-2020.
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10-18. doi: 10.12932/AP-200220-0773. PMID: 32134278.
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-76. doi: 10.1016/j.ijsu.2020.02.034.
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-280. doi: 10.1111/tmi.13383.
Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi: 10.1038/s41467-020-16256-y.
Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2021;51(4):1107-1110. doi: 10.1007/s11239-020-02105-8.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Advances in Clinical Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.